Stock Analysis Report

Executive Summary

MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies.

Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Similar Companies

Share Price & News

How has MolMed's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: 4HW has not had significant price volatility in the past 3 months.

Market Performance

7 Day Return




DE Biotechs


DE Market

1 Year Return




DE Biotechs


DE Market

Return vs Industry: 4HW exceeded the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: 4HW exceeded the German Market which returned 13.7% over the past year.

Shareholder returns

7 Day-0.7%-2.3%-0.2%
30 Day0.3%-3.2%0.3%
90 Day6.8%6.3%3.7%
1 Year36.6%36.6%8.6%8.4%17.2%13.7%
3 Year-11.7%-11.7%44.5%42.9%15.4%5.3%
5 Year-10.5%-25.4%13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is MolMed's share price compared to the market and industry in the last 5 years?

Simply Wall St News

No news available


Is MolMed undervalued compared to its fair value and its price relative to the market?


Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4HW's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4HW's fair value to establish if it is undervalued.

Price To Earnings Ratio

PE vs Industry: 4HW is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 4HW is unprofitable, so we can't compare its PE Ratio to the German market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4HW's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 4HW is overvalued based on its PB Ratio (7.5x) compared to the DE Biotechs industry average (3.5x).

Next Steps

Future Growth

How is MolMed forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MolMed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Next Steps

Past Performance

How has MolMed performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4HW is currently unprofitable.

Growing Profit Margin: 4HW is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 4HW is unprofitable, but has reduced losses over the past 5 years at a rate of 29.2% per year.

Accelerating Growth: Unable to compare 4HW's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4HW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).

Return on Equity

High ROE: 4HW has a negative Return on Equity (-7.65%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Next Steps

Financial Health

How is MolMed's financial position?

Financial Position Analysis

Short Term Liabilities: 4HW's short term assets (€26.6M) exceed its short term liabilities (€15.0M).

Long Term Liabilities: 4HW's short term assets (€26.6M) exceed its long term liabilities (€11.3M).

Debt to Equity History and Analysis

Debt Level: 4HW is debt free.

Reducing Debt: 4HW has no debt compared to 5 years ago when its debt to equity ratio was 22.7%.

Balance Sheet

Inventory Level: 4HW has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 4HW's debt is covered by short term assets.

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4HW has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 4HW has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 11.1% each year.

Next Steps


What is MolMed's current dividend yield, its reliability and sustainability?

Dividend Yield vs Market


Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 4HW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 4HW's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4HW's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4HW's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4HW's dividend in 3 years as they are not forecast to pay a notable one for the German market.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Riccardo Palmisano 0





Dr. Riccardo Palmisano has been Chief Executive Officer of MolMed S.p.A since December 11, 2015 and has been its Director since October 2015. 

CEO Compensation Analysis

Compensation vs Market: Riccardo's total compensation ($USD633.50K) is about average for companies of similar size in the German market ($USD625.18K).

Compensation vs Earnings: Riccardo's compensation has been consistent with company performance over the past year.

Board Members

Riccardo Palmisano
CEO & Director4.2yrs€587.00kno data
Claudio Bordignon
Founder & Chairman of Scientific Board0yrs€470.65kno data
Sabina Grossi
Director6.8yrs€46.00kno data
Alfredo Messina
Director6.8yrs€22.00kno data
Laura Ferro
Independent Director3.8yrs€30.00kno data
Carlo Incerti
Chairman of the Board1.4yrs€85.00kno data
Alberto Carletti
Non-Independent & Non-Executive Director6.8yrs€23.00kno data
Mario Masciocchi
Lead Independent Director0yrs€53.00kno data
Raffaella Ruggiero
Independent Director6.8yrs€34.00kno data
Riccardo Perotta
Chairman of Statutory Auditor0yrsno datano data


Average Tenure


Average Age

Experienced Board: 4HW's board of directors are considered experienced (6.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6%.

Top Shareholders

Company Information

MolMed S.p.A.'s company bio, employee growth, exchange listings and data sources

Key Information

  • Name: MolMed S.p.A.
  • Ticker: 4HW
  • Exchange: DB
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €182.600m
  • Shares outstanding: 463.45m
  • Website: https://www.molmed.com

Number of Employees


  • MolMed S.p.A.
  • Via Olgettina, 58
  • Milan
  • Milan
  • 20132
  • Italy


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MLMBIT (Borsa Italiana)YesCommon SharesITEURMar 2008
0IE3LSE (London Stock Exchange)YesCommon SharesGBEURMar 2008
4HWDB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2008
MLMMBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURMar 2008


MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. The company’s pipeline include Zalmoxis (TK), a cell based therapy product, which is in Phase III clinical trial that is used for the treatment of hematological malignancies. Its products pipeline also comprise NGR-hTNF, a biological drug for the treatment of solid tumors, which displays antitumor activity through its specific binding to blood vessels feeding the tumor mass. In addition, the company’s preclinical development product includes CAR-CD44v6, an immuno-gene therapy project for the treatment of various hematological malignancies and epithelial tumors. Further, it conducts cell and gene therapy projects in collaboration with third parties, such as the cGMP production of clinical-grade viral vectors; and manufacturing of patient-specific genetically engineered cells. MolMed S.p.A. was founded in 1996 and is headquartered in Milan, Italy. 

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 22:04
End of Day Share Price2020/02/20 00:00
Annual Earnings2018/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.